drugset
drugset / Trial / NCT05319015

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

NCT05319015 ↗

Phase 2 Recruiting 30 enrolled University of Texas Southwestern Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.

Timeline

Start
2023-01-06
Primary completion
2026-07
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 20 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

renal cell carcinoma